e-learning
resources
Glasgow 2004
Sunday 05.09.2004
Community acquired pneumonia
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Costs of treatment of hospitalised community-acquired pneumonia from the hospitals’ perspective – a prospective study comparing moxifloxacin with other antibiotic treatment alternatives
T. T. Bauer, T. Pfeil, C. Ernen, D. Daniel, B. M. Schlosser, I. M. Thate-Waschke, R. Rychlik (Bochum, Burscheid, Leverkusen, Germany)
Source:
Annual Congress 2004 - Community acquired pneumonia
Session:
Community acquired pneumonia
Session type:
Thematic Poster Session
Number:
1178
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. T. Bauer, T. Pfeil, C. Ernen, D. Daniel, B. M. Schlosser, I. M. Thate-Waschke, R. Rychlik (Bochum, Burscheid, Leverkusen, Germany). Costs of treatment of hospitalised community-acquired pneumonia from the hospitals’ perspective – a prospective study comparing moxifloxacin with other antibiotic treatment alternatives. Eur Respir J 2004; 24: Suppl. 48, 1178
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Trends in empiric antimicrobial therapy and efficiency of care for community-acquired pneumonia in hospitalized Belarussian patients
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007
Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial
Source: Eur Respir J, 58 (2) 2002535; 10.1183/13993003.02535-2020
Year: 2021
Influence of adherence to clinical guidelines in empiric antibiotics choice on outcomes of community-acquired pneumonia in hospitalized Belarussian patients
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005
Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005
The extent of microbiological testing and antibiotic de-escalation in adults with community-acquired pneumonia: a retrospective cohort study.
Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection
Year: 2018
The effects of antibiotic therapy at the pre-hospital stage on the in-hospital mortality in adults with community-acquired pneumonia in Russia: observational study results.
Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice
Year: 2020
A clinical and outcomes assessment of the management of community-acquired pneumonia (CAP): a multinational, prospective, double-blind comparison of moxifloxacin to standard first-line oral monotherapy or combination regimen
Source: Eur Respir J 2001; 18: Suppl. 33, 189s
Year: 2001
Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia: a cohort study
Source: Eur Respir J, 54 (1) 1900057; 10.1183/13993003.00057-2019
Year: 2019
Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP
Source: Eur Respir J 2013; 41: 123-130
Year: 2013
The impact of adherence to guidelines for hospitalized community-acquired pneumonia on health outcomes and mortality: A retrospective cohort study
Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management
Year: 2015
Antibiotic therapy of community-acquired pneumonia in the hospital setting: national guidelines and real clinical practice.
Source: International Congress 2017 – COPD management
Year: 2017
The impact of a stewardship programme on outcomes in patients admitted with community-acquired pneumonia
Source: Virtual Congress 2020 – Antibiotic therapy for pneumonia and pleural infections
Year: 2020
The approach to antibiotic treatment in community-acquired pneumonia
Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia
Year: 2008
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010
Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia
Source: Eur Respir J 2003; 21: 135-143
Year: 2003
The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 733s
Year: 2006
Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis
Source: Eur Respir J 2008; 31: 1068-1076
Year: 2008
Implementation of severity guided antibiotic treatment according to Dutch guidelines in hospitalized patients with community-acquired pneumonia (CAP) included in a clinical trial
Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections
Year: 2011
GRACE-01 Genomics to combat resistance against antibiotics in community-acquired LRTI in Europe – a multicentre, observational cohort study of cough/LRTI in primary care
Source: Annual Congress 2007 - Clinical trial: antibiotic use in the community
Year: 2007
Comparative prospective cohort study of the efficacy and safety according to dose of Ceftriaxone in community-acquired pneumonia
Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept